Preconditioning and postconditioning: New strategies for cardioprotection

Diabetes, Obesity and Metabolism

Volumn 10, Issue 6, 2008, Pages 451-459

  Hausenloy, D J ^a   Yellon, D M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Diabetes; Metabolic syndrome; Postconditioning; Preconditioning; Reperfusion

Indexed keywords

ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTITHROMBOCYTIC AGENT; ATRIAL NATRIURETIC FACTOR; ATRIAL NATRIURETIC FACTOR ALPHA; CYCLOSPORIN A; ERYTHROPOIETIN; FIBRINOLYTIC AGENT; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; POTASSIUM; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE;

ACUTE HEART INFARCTION; CLINICAL TRIAL; CORONARY REPERFUSION; DIABETES MELLITUS; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; ISCHEMIC POSTCONDITIONING; ISCHEMIC PRECONDITIONING; METABOLIC SYNDROME X; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PERCUTANEOUS CORONARY INTERVENTION; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

EID: 43149118346     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2007.00762.x     Document Type: Review

References (91)

1. 1 Weir RA, McMurray JJ, Velazquez EJ. Epidemiology of heart failure and left ventricular systolic dysfunction after acute myocardial infarction: prevalence, clinical characteristics, and prognostic importance. Am J Cardiol 2006 ; 97: 13F–25F.
2. 2 Andersen HR, Nielsen TT, Rasmussen K et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 2003 ; 349: 733–742.
3. 3 Sabatine MS, Cannon CP, Gibson CM et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST‐segment elevation. N Engl J Med 2005 ; 352: 1179–1189.
4. 4 Smith JW, Marcus FI, Serokman R. Prognosis of patients with diabetes mellitus after acute myocardial infarction. Am J Cardiol 1984 ; 54: 718–721.
5. 5 Abbud ZA, Shindler DM, Wilson AC, Kostis JB. Effect of diabetes mellitus on short‐ and long‐term mortality rates of patients with acute myocardial infarction: a statewide study. Myocardial Infarction Data Acquisition System Study Group. Am Heart J 1995 ; 130: 51–58.
6. 6 Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998 ; 339: 229–234.
7. 7 Isomaa B, Almgren P, Tuomi T et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001 ; 24: 683–689.
8. 8 Malik S, Wong ND, Franklin SS et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004 ; 110: 1245–1250.
9. 9 Schwartz GG, Olsson AG, Szarek M, Sasiela WJ. Relation of characteristics of metabolic syndrome to short‐term prognosis and effects of intensive statin therapy after acute coronary syndrome: an analysis of the myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) trial. Diabetes Care 2005 ; 28: 2508–2513.
10. 10 Zeller M, Steg PG, Ravisy J et al. Prevalence and impact of metabolic syndrome on hospital outcomes in acute myocardial infarction. Arch Intern Med 2005 ; 165: 1192–1198.
11. 11 Clavijo LC, Pinto TL, Kuchulakanti PK et al. Metabolic syndrome in patients with acute myocardial infarction is associated with increased infarct size and in‐hospital complications. Cardiovasc Revasc Med 2006 ; 7: 7–11.
12. 12 Celik T, Turhan H, Kursaklioglu H et al. Impact of metabolic syndrome on myocardial perfusion grade after primary percutaneous coronary intervention in patients with acute ST elevation myocardial infarction. Coron Artery Dis 2006 ; 17: 339–343.
13. 13 Maroko PR, Kjekshus JK, Sobel BE et al. Factors influencing infarct size following experimental coronary artery occlusions. Circulation 1971 ; 43: 67–82.
14. 14 Maroko PR, Libby P, Ginks WR et al. Coronary artery reperfusion. I. Early effects on local myocardial function and the extent of myocardial necrosis. J Clin Invest 1972 ; 51: 2710–2716.
15. 15 Ginks WR, Sybers HD, Maroko PR, Covell JW, Sobel BE, Ross J Jr. Coronary artery reperfusion. II. Reduction of myocardial infarct size at 1 week after the coronary occlusion. J Clin Invest 1972 ; 51: 2717–2723.
16. 16 Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986 ; 74: 1124–1136.
17. 17 Yellon DM, Downey JM. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev 2003 ; 83: 1113–1151.
18. 18 Marber MS, Latchman DS, Walker JM, Yellon DM. Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction. Circulation 1993 ; 88: 1264–1272.
19. 19 Kuzuya T, Hoshida S, Yamashita N et al. Delayed effects of sublethal ischemia on the acquisition of tolerance to ischemia. Circ Res 1993 ; 72: 1293–1299.
20. 20 Przyklenk K, Bauer B, Ovize M, Kloner RA, Whittaker P. Regional ischemic ‘preconditioning’ protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation 1993 ; 87: 893–899.
21. 21 Bolli R. The late phase of preconditioning. Circ Res 2000 ; 87: 972–983.
22. 22 Stein AB, Tang XL, Guo Y, Xuan YT, Dawn B, Bolli R. Delayed adaptation of the heart to stress: late preconditioning. Stroke 2004 ; 35 (11 Suppl. 1): 2676–2679.
23. 23 Heusch G, Schulz R. Remote preconditioning. J Mol Cell Cardiol 2002 ; 34: 1279–1281.
24. 24 Przyklenk K, Darling CE, Dickson EW, Whittaker P. Cardioprotection ‘outside the box’–the evolving paradigm of remote preconditioning. Basic Res Cardiol 2003 ; 98: 149–157.
25. 25 Costa AD, Garlid KD, West IC et al. Protein kinase G transmits the cardioprotective signal from cytosol to mitochondria. Circ Res 2005 ; 97: 329–336.
26. 26 Jaburek M, Costa AD, Burton JR, Costa CL, Garlid KD. Mitochondrial PKC{epsilon} and mitochondrial ATP‐Sensitive K+ channel copurify and coreconstitute to form a functioning signaling module in proteoliposomes. Circ Res 2006 ; 99: 878–883.
27. 27 Andrukhiv A, Costa AD, West IC, Garlid KD. Opening mitoKATP increases superoxide generation from complex I of the electron transport chain. Am J Physiol Heart Circ Physiol 2006 ; 291: H2067–H2074.
28. 28 Costa AD, Jakob R, Costa CL, Andrukhiv K, West IC, Garlid KD. The mechanism by which the mitochondrial ATP‐sensitive K+ channel opening and H2O2 inhibit the mitochondrial permeability transition. J Biol Chem 2006 ; 281: 20801–20808.
29. 29 Crompton M, Barksby E, Johnson N, Capano M. Mitochondrial intermembrane junctional complexes and their involvement in cell death. Biochimie 2002 ; 84: 143–152.
30. 30 Hausenloy DJ, Yellon DM. The mitochondrial permeability transition pore: its fundamental role in mediating cell death during ischaemia and reperfusion. J Mol Cell Cardiol 2003 ; 35: 339–341.
31. 31 Solenkova NV, Solodushko V, Cohen MV, Downey JM. Endogenous adenosine protects the preconditioned heart during the early minutes of reperfusion by activating Akt. Am J Physiol Heart Circ Physiol 2006 ; 290: H441–H449.
32. 32 Hausenloy DJ, Tsang A, Mocanu M, Yellon DM. Ischemic preconditioning protects by activating pro‐survival kinases at reperfusion. Am J Physiol Heart Circ Physiol 2005 ; 288: H971–H976.
33. 33 Lecour S, Suleman N, Deuchar GA et al. Pharmacological preconditioning with tumor necrosis factor‐alpha activates signal transducer and activator of transcription‐3 at reperfusion without involving classic prosurvival kinases (Akt and extracellular signal‐regulated kinase). Circulation 2005 ; 112: 3911–3918.
34. 34 Hausenloy DJ, Maddock HL, Baxter GF, Yellon DM. Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning? Cardiovasc Res 2002 ; 55: 534–543.
35. 35 Javadov SA, Clarke S, Das M, Griffiths EJ, Lim KH, Halestrap AP. Ischaemic preconditioning inhibits opening of mitochondrial permeability transition pores in the reperfused rat heart. J Physiol 2003 ; 549: 513–524.
36. 36 Hausenloy DJ, Yellon DM, Mani‐Babu S, Duchen MR. Preconditioning protects by inhibiting the mitochondrial permeability transition. Am J Physiol Heart Circ Physiol 2004 ; 287: H841–H849.
37. 37 Davidson SM, Hausenloy D, Duchen MR, Yellon DM. Signalling via the reperfusion injury signalling kinase (RISK) pathway links closure of the mitochondrial permeability transition pore to cardioprotection. Int J Biochem Cell Biol 2006 ; 38: 414–419.
38. 38 Matsumoto‐Ida M, Akao M, Takeda T, Kato M, Kita T. Real‐time 2‐photon imaging of mitochondrial function in perfused rat hearts subjected to ischemia/reperfusion. Circulation 2006 ; 114: 1497–1503.
39. 39 Yellon DM, Baxter GF. Reperfusion injury revisited: is there a role for growth factor signaling in limiting lethal reperfusion injury? Trends Cardiovasc Med 1999 ; 9: 245–249.
40. 40 Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia‐reperfusion injury: targeting the reperfusion injury salvage kinase (RISK)‐pathway. Cardiovasc Res 2004 ; 61: 448–460.
41. 41 Zhao ZQ, Corvera JS, Halkos ME et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2003 ; 285: H579–H588.
42. 42 Vinten‐Johansen J, Yellon DM, Opie LH. Postconditioning: a simple, clinically applicable procedure to improve revascularization in acute myocardial infarction. Circulation 2005 ; 112: 2085–2088.
43. 43 Yellon DM, Opie LH. Postconditioning for protection of the infarcting heart. Lancet 2006 ; 367: 456–458.
44. 44 Kerendi F, Kin H, Halkos ME et al. Remote postconditioning. Brief renal ischemia and reperfusion applied before coronary artery reperfusion reduces myocardial infarct size via endogenous activation of adenosine receptors. Basic Res Cardiol 2005 ; 100: 404–412.
45. 45 Laskey WK. Brief repetitive balloon occlusions enhance reperfusion during percutaneous coronary intervention for acute myocardial infarction: a pilot study. Catheter Cardiovasc Interv 2005 ; 65: 361–367.
46. 46 Staat P, Rioufol G, Piot C et al. Postconditioning the human heart. Circulation 2005 ; 112: 2143–2148.
47. 47 Ma X, Zhang X, Li C, Luo M. Effect of postconditioning on coronary blood flow velocity and endothelial function and LV recovery after myocardial infarction. J Interv Cardiol 2006 ; 19: 367–375.
48. 48 Yang X‐C, Liu Y, Wang L‐F et al. Permanent reduction in myocardial infarct size by postconditioning in patients after primary coronary angioplasty. Circulation 2006 ; 114: II–812.
49. 49 Sun HY, Wang NP, Kerendi F et al. Hypoxic postconditioning reduces cardiomyocyte loss by inhibiting ROS generation and intracellular Ca2+ overload. Am J Physiol Heart Circ Physiol 2005 ; 288: H1900–H1908.
50. 50 Philipp S, Yang XM, Cui L, Davis AM, Downey JM, Cohen MV. Postconditioning protects rabbit hearts through a protein kinase C‐adenosine A2b receptor cascade. Cardiovasc Res 2006 ; 70: 308–314.
51. 51 Kin H, Zatta AJ, Lofye MT et al. Postconditioning reduces infarct size via adenosine receptor activation by endogenous adenosine. Cardiovasc Res 2005 ; 67: 124–133.
52. 52 Tsang A, Hausenloy DJ, Mocanu MM, Yellon DM. Postconditioning: a form of “modified reperfusion” protects the myocardium by activating the phosphatidylinositol 3‐kinase‐Akt pathway. Circ Res 2004 ; 95: 230–232.
53. 53 Darling CE, Jiang R, Maynard M, Whittaker P, Vinten‐Johansen J, Przyklenk K. ‘Postconditioning’ via stuttering reperfusion limits myocardial infarct size in rabbit hearts: role of ERK 1/2. Am J Physiol Heart Circ Physiol 2005 ; 289: H1618–H1626.
54. 54 Yang XM, Proctor JB, Cui L, Krieg T, Downey JM, Cohen MV. Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways. J Am Coll Cardiol 2004 ; 44: 1103–1110.
55. 55 Argaud L, Gateau‐Roesch O, Raisky O, Loufouat J, Robert D, Ovize M. Postconditioning inhibits mitochondrial permeability transition. Circulation 2005 ; 111: 194–197.
56. 56 Hausenloy DJ, Tsang A, Yellon DM. The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning. Trends Cardiovasc Med 2005 ; 15: 69–75.
57. 57 Hausenloy DJ, Yellon DM. Survival kinases in ischemic preconditioning and postconditioning. Cardiovasc Res 2006 ; 70: 240–253.
58. 58 Paulson DJ. The diabetic heart is more sensitive to ischemic injury. Cardiovasc Res 1997 ; 34: 104–112.
59. 59 Tatsumi T, Matoba S, Kobara M et al. Energy metabolism after ischemic preconditioning in streptozotocin‐induced diabetic rat hearts. J Am Coll Cardiol 1998 ; 31: 707–715.
60. 60 Ravingerova T, Stetka R, Pancza D, Ulicna O, Ziegelhoffer A, Styk J. Susceptibility to ischemia‐induced arrhythmias and the effect of preconditioning in the diabetic rat heart. Physiol Res 2000 ; 49: 607–616.
61. 61 Kersten JR, Toller WG, Gross ER, Pagel PS, Warltier DC. Diabetes abolishes ischemic preconditioning: role of glucose, insulin, and osmolality. Am J Physiol Heart Circ Physiol 2000 ; 278: H1218–H1224.
62. 62 Nieszner E, Posa I, Kocsis E, Pogatsa G, Preda I, Koltai MZ. Influence of diabetic state and that of different sulfonylureas on the size of myocardial infarction with and without ischemic preconditioning in rabbits. Exp Clin Endocrinol Diabetes 2002 ; 110: 212–218.
63. 63 Tosaki A, Pali T, Droy‐Lefaix MT. Effects of Ginkgo biloba extract and preconditioning on the diabetic rat myocardium. Diabetologia 1996 ; 39: 1255–1262.
64. 64 Tosaki A, Engelman DT, Engelman RM, Das DK. The evolution of diabetic response to ischemia/reperfusion and preconditioning in isolated working rat hearts. Cardiovasc Res 1996 ; 31: 526–536.
65. 65 Ravingerova T, Stetka R, Volkovova K et al. Acute diabetes modulates response to ischemia in isolated rat heart. Mol Cell Biochem 2000 ; 210: 143–151.
66. 66 Del Valle HF, Lascano EC, Negroni JA, Crottogini AJ. Absence of ischemic preconditioning protection in diabetic sheep hearts: role of sarcolemmal KATP channel dysfunction. Mol Cell Biochem 2003 ; 249: 21–30.
67. 67 Huisamen B. Protein kinase B in the diabetic heart. Mol Cell Biochem 2003 ; 249: 31–38.
68. 68 Tsang A, Hausenloy DJ, Mocanu MM, Carr RD, Yellon DM. Preconditioning the diabetic heart: the importance of akt phosphorylation. Diabetes 2005 ; 54: 2360–2364.
69. 69 Wynne A, Hausenloy DJ, Mocanu M, Yellon DM. Glimepiride reduces the threshold for ischemic preconditioning in the diabetic heart. J Mol Cell Cardiol 2007 ; 42: S177.
70. 70 Yue TL, Bao W, Gu JL et al. Rosiglitazone treatment in Zucker diabetic Fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion‐induced myocardial injury. Diabetes 2005 ; 54: 554–562.
71. 71 Hausenloy DJ, Wynne A, Mocanu M, Yellon DM. The metabolic syndrome raises the threshold for cardioprotection. J Mol Cell Cardiol 2007 ; 42: S185.
72. 72 Reussner C, Kloting I, Strasser R, Weinbrenner C. Postconditioning fails to reduce the infarct sizes in hearts from rats with metabolic syndrome: role of glycogen synthase kinase 3beta [abstract]. J Mol Cell Cardiol 2006 ; 40.
73. 73 Maddock HL, Siedlecka SM, Yellon DM. Myocardial protection from either ischaemic preconditioning or nicorandil is not blocked by gliclazide. Cardiovasc Drugs Ther 2004 ; 18: 113–119.
74. 74 Flynn DM, Smith AH, Treadway JL et al. The sulfonylurea glipizide does not inhibit ischemic preconditioning in anesthetized rabbits. Cardiovasc Drugs Ther 2005 ; 19: 337–346.
75. 75 Mocanu MM, Maddock HL, Baxter GF, Lawrence CL, Standen NB, Yellon DM. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation 2001 ; 103: 3111–3116.
76. 76 Yao Z, Gross GJ. Glibenclamide antagonizes adenosine A1 receptor‐mediated cardioprotection in stunned canine myocardium. Circulation 1993 ; 88: 235–244.
77. 77 Turner RC, Holman RR, Cull CA et al. Effect of intensive blood‐glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 ; 352: 854–865.
78. 78 Bell RM, Yellon DM. Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up‐regulating a pro‐survival pathway. J Am Coll Cardiol 2003 ; 41: 508–515.
79. 79 Jonassen AK, Sack MN, Mjos OD, Yellon DM. Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell‐survival signaling. Circ Res 2001 ; 89: 1191–1198.
80. 80 Gao F, Gao E, Yue TL et al. Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia‐reperfusion: the roles of PI3‐kinase, Akt, and endothelial nitric oxide synthase phosphorylation. Circulation 2002 ; 105: 1497–1502.
81. 81 Parsa CJ, Matsumoto A, Kim J et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 2003 ; 112: 999–1007.
82. 82 Bullard AJ, Govewalla P, Yellon DM. Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo. Basic Res Cardiol 2005 ; 100: 397–403.
83. 83 Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon‐like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005 ; 54: 146–151.
84. 84 Bose AK, Mocanu MM, Carr RD, Yellon DM. Glucagon like peptide‐1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model. Cardiovasc Drugs Ther 2005 ; 19: 9–11.
85. 85 Mehta SR, Yusuf S, Diaz R et al. Effect of glucose‐insulin‐potassium infusion on mortality in patients with acute ST‐segment elevation myocardial infarction: the CREATE‐ECLA randomized controlled trial. JAMA 2005 ; 293: 437–446.
86. 86 Jonassen AK, Aasum E, Riemersma RA, Mjos OD, Larsen TS. Glucose‐insulin‐potassium reduces infarct size when administered during reperfusion. Cardiovasc Drugs Ther 2000 ; 14: 615–623.
87. 87 Ehrenreich H, Hasselblatt M, Dembowski C et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002 ; 8: 495–505.
88. 88 Lipsic E, Van Der MP, Voors AA et al. A single bolus of a long‐acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drugs Ther 2006 ; 20: 135–141.
89. 89 Nikolaidis LA, Mankad S, Sokos GG et al. Effects of glucagon‐like peptide‐1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004 ; 109: 962–965.
90. 90 Yang XM, Philipp S, Downey JM, Cohen MV. Atrial natriuretic peptide administered just prior to reperfusion limits infarction in rabbit hearts. Basic Res Cardiol 2006 ; 101: 311–318.
91. 91 Asakura M, Jiyoong K, Minamino T, Shintani Y, Asanuma H, Kitakaze M. Rationale and design of a large‐scale trial using atrial natriuretic peptide (ANP) as an adjunct to percutaneous coronary intervention for ST‐segment elevation acute myocardial infarction: Japan‐Working groups of acute myocardial infarction for the reduction of Necrotic Damage by ANP (J‐WIND‐ANP). Circ J 2004 ; 68: 95–100.